Tylenol Ads Touting Superior Safety To NSAIDs May Mislead Consumers – NAD
This article was originally published in The Tan Sheet
Executive Summary
Ads for Tylenol Arthritis Pain claiming the analgesic has fewer drug interactions than Advil and Aleve could be misinterpreted by consumers and should be modified or discontinued, the National Advertising Division concludes in an upcoming Case Reports
You may also be interested in...
Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
Use of a "black box" warning on OTC acetaminophen labeling would be an inappropriate means for alerting consumers about potential liver damage, two consultants to FDA's Nonprescription Drugs Advisory Committee said Sept. 19
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands